Immunocore announces dosing of first patient with third ImmTAC® bispecific

IMC-C103C studied in various MAGE-A4 expressing solid tumours

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 December 2019) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announced the start of the first-in-human clinical trial of IMC-C103C, the third bispecific developed using the company’s innovative ImmTAC® technology platform. IMC-C103C is focused on targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4) and is being developed in partnership with Genentech, a member of the Roche Group.